DiaMedica Therapeutics Inc. (DMAC)

NASDAQ: DMAC · Real-Time Price · USD
3.505
-0.035 (-0.99%)
Apr 21, 2025, 4:00 PM EDT - Market closed
-0.99%
Market Cap 150.21M
Revenue (ttm) n/a
Net Income (ttm) -24.44M
Shares Out 42.86M
EPS (ttm) -0.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 72,546
Open 3.470
Previous Close 3.540
Day's Range 3.370 - 3.505
52-Week Range 2.140 - 6.820
Beta 1.49
Analysts Strong Buy
Price Target 8.00 (+128.25%)
Earnings Date May 7, 2025

About DMAC

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the trea... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 28
Stock Exchange NASDAQ
Ticker Symbol DMAC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for DMAC stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 128.25% from the latest price.

Price Target
$8.0
(128.25% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Call Transcript

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2024 Earnings Conference Call March 18, 2025 8:00 AM ET Company Participants Rick Pauls - President and CEO Lorianne Masuoka - CMO Scott Kellen - CFO Conf...

4 weeks ago - Seeking Alpha

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, ...

5 weeks ago - Business Wire

DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced toda...

5 weeks ago - Business Wire

DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of ...

2 months ago - Business Wire

DiaMedica Therapeutics Announces Publication of DM199's Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announce...

2 months ago - Business Wire

DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced toda...

2 months ago - Business Wire

DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, is excited to ...

4 months ago - Business Wire

DiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call Transcript

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Rick Pauls - President, Chief Executive Officer & Director Scott Kellen - ...

5 months ago - Seeking Alpha

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today provided...

5 months ago - Business Wire

DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announce...

5 months ago - Business Wire

DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced toda...

5 months ago - Business Wire

DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced toda...

5 months ago - Business Wire

DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announce...

6 months ago - Business Wire

DiaMedica Therapeutics Upcoming Conference Participation

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute...

8 months ago - Business Wire

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today provided...

9 months ago - Business Wire

DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute...

9 months ago - Business Wire

DiaMedica: Early 2025 Interim Futility Analysis Could Be A Major Inflection Point

An interim futility analysis by the DSMB of DM199 for patients with AIS in the phase 2/3 ReMEDy2 trial is expected by Q1 of 2025. The global acute ischemic stroke therapeutics market size is expected ...

10 months ago - Seeking Alpha

DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced...

10 months ago - Business Wire

DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced...

10 months ago - Business Wire

DiaMedica Therapeutics Announces $11.8 Million Private Placement

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announce...

10 months ago - Business Wire

DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announce...

10 months ago - Business Wire

DiaMedica Therapeutics Inc. (DMAC) Q1 2024 Earnings Call Transcript

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2024 Results Conference Call May 9, 2024 8:00 AM ET Company Participants Rick Pauls - President, CEO & Director Lorianne Masuoka - Chief Medical Officer S...

1 year ago - Seeking Alpha

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal ...

1 year ago - Business Wire

DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute...

1 year ago - Business Wire

DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal ...

1 year ago - Business Wire